Log in

NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

$12.67
+0.11 (+0.88 %)
(As of 03/30/2020 06:20 AM ET)
Today's Range
$11.90
Now: $12.67
$13.31
50-Day Range
$10.00
MA: $14.17
$19.28
52-Week Range
$6.30
Now: $12.67
$20.40
Volume163,678 shs
Average Volume444,580 shs
Market Capitalization$582.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.61
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Read More
Arcus Biosciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-694-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15 million
Book Value$3.57 per share

Profitability

Net Income$-84,710,000.00
Net Margins-564.73%

Miscellaneous

Employees108
Market Cap$582.44 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.


Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

How has Arcus Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCUS stock has decreased by 25.3% and is now trading at $12.67. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arcus Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcus Biosciences.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Arcus Biosciences.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences Inc (NYSE:RCUS) announced its earnings results on Thursday, March, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.13. The firm earned $9.75 million during the quarter, compared to analysts' expectations of $1.37 million. Arcus Biosciences had a negative net margin of 564.73% and a negative return on equity of 44.63%. View Arcus Biosciences' earnings history.

What price target have analysts set for RCUS?

5 equities research analysts have issued 12-month price objectives for Arcus Biosciences' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate Arcus Biosciences' stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 59.8% from the stock's current price. View analysts' price targets for Arcus Biosciences.

Has Arcus Biosciences been receiving favorable news coverage?

News stories about RCUS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutArcus Biosciences.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a decline in short interest in March. As of March 13th, there was short interest totaling 948,200 shares, a decline of 37.6% from the February 27th total of 1,520,000 shares. Based on an average daily volume of 247,400 shares, the days-to-cover ratio is currently 3.8 days. Approximately 2.9% of the company's stock are sold short. View Arcus Biosciences' Current Options Chain.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
  • Mr. Steven Chan, Consultant (Age 47)
  • Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 50)

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Invus Financial Advisors LLC (4.02%), Boxer Capital LLC (3.65%), EcoR1 Capital LLC (1.59%), State Street Corp (1.40%), Geode Capital Management LLC (0.86%) and Janus Henderson Group PLC (0.65%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View institutional ownership trends for Arcus Biosciences.

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Platinum Investment Management Ltd., EcoR1 Capital LLC, Credit Suisse AG, and New York State Common Retirement Fund. View insider buying and selling activity for Arcus Biosciences.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was purchased by a variety of institutional investors in the last quarter, including Invus Financial Advisors LLC, Boxer Capital LLC, Algert Global LLC, Renaissance Technologies LLC, Prudential Financial Inc., Nuveen Asset Management LLC, California Public Employees Retirement System, and Jacobs Levy Equity Management Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg, and Terry J Rosen. View insider buying and selling activity for Arcus Biosciences.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $12.67.

How big of a company is Arcus Biosciences?

Arcus Biosciences has a market capitalization of $582.44 million and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe. View additional information about Arcus Biosciences.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is http://www.arcusbio.com/.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]


MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel